Please assess the completion status of the following clinical trial:

Trial Title: Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female subjects 55 to 80 years with histologically or cytologically documented primary intraductal or lobular invasive breast cancer that meets the following criteria:~* T2, N0 or N1, M0.~* Primary tumour clinically determined to be 2 to 5 cm in the greatest dimension.~* Laboratory documentation of positive oestrogen receptor (ER+) status in at least 10% of the tumour cells.~* Laboratory documentation of HER-2 negative status.~Postmenopausal defined as~* no spontaneous menses for a total of 2 years~* amenorrheic for at least 12 months with serum oestrogen level \<30 pg/mL, and both luteinising hormone (LH)/follicle stimulating hormone (FSH) \>20 IU/L, chemotherapy-induced amenorrhoea for at least 12 months~* bilateral oophorectomy, or radiation castration and amenorrhoeic for at least 3 months.~Eastern Cooperative Oncology Group (ECOG) performance status ≤2.~Exclusion Criteria:~* Has locally advanced breast cancer that is considered non-operable without neoadjuvant therapy.~* Has evidence of metastatic disease~* as a diagnosis of inflammatory breast cancer~* Has ductal carcinoma in situ

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BN83495 (Type: EXPERIMENTAL): 40mg tablet oral daily administration from Day 1 to Day 14.

Based on this trial design, predict the completion outcome and termination type (if applicable).